Ovid Therapeutics Inc. Earnings Per Share (Basic)
Ovid Therapeutics Inc. (OVID) reported Earnings Per Share (Basic) of -$0.20 per share for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2024-11-12
- Ovid Therapeutics Inc. earnings per share, basic for the quarter ending 2024-09-30 was -$0.20.
- Ovid Therapeutics Inc. earnings per share, basic for the quarter ending 2024-06-30 was $0.12.
- Ovid Therapeutics Inc. earnings per share, basic for the quarter ending 2024-03-31 was -$0.17.
- Ovid Therapeutics Inc. earnings per share, basic for the quarter ending 2023-12-31 was -$0.22.
- Ovid Therapeutics Inc. earnings per share, basic for fiscal 2023 was -$0.74.
- Ovid Therapeutics Inc. earnings per share, basic for fiscal 2022 was -$0.77, a 143.26% decline from fiscal 2021.
- Ovid Therapeutics Inc. earnings per share, basic for fiscal 2021 was $1.78.
- Ovid Therapeutics Inc. earnings per share, basic for fiscal 2020 was -$1.39.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$0.20 10-Q · filed 2024-11-12 | -$0.08 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.24 10-Q · filed 2024-11-12 | -$0.46 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2024-06-30 | $0.12 10-Q · filed 2024-08-13 | -$0.04 10-Q · filed 2024-08-13 | -$0.26 derived: net income ÷ weighted average shares · filed 2024-08-13 | -$0.42 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2024-03-31 | -$0.17 10-Q · filed 2024-05-14 | -$0.38 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$0.54 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.72 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2023-12-31 | -$0.22 derived: net income ÷ weighted average shares · filed 2024-03-08 | -$0.38 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.55 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.74 10-K · filed 2024-03-08 |
| 2023-09-30 | -$0.16 10-Q · filed 2024-11-12 | -$0.34 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.52 10-Q · filed 2024-11-12 | -$0.69 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2023-06-30 | -$0.18 10-Q · filed 2024-08-13 | -$0.37 10-Q · filed 2024-08-13 | -$0.53 derived: net income ÷ weighted average shares · filed 2024-08-13 | -$0.70 derived: net income ÷ weighted average shares · filed 2024-08-13 |
| 2023-03-31 | -$0.19 10-Q · filed 2024-05-14 | -$0.35 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$0.52 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$0.73 derived: net income ÷ weighted average shares · filed 2024-05-14 |
| 2022-12-31 | -$0.16 derived: net income ÷ weighted average shares · filed 2024-03-08 | -$0.33 derived: net income ÷ weighted average shares · filed 2024-03-08 | -$0.54 derived: net income ÷ weighted average shares · filed 2024-03-08 | -$0.77 10-K · filed 2024-03-08 |
| 2022-09-30 | -$0.17 10-Q · filed 2023-11-03 | -$0.38 derived: net income ÷ weighted average shares · filed 2023-11-03 | -$0.61 10-Q · filed 2023-11-03 | -$0.97 derived: net income ÷ weighted average shares · filed 2023-11-03 |
| 2022-06-30 | -$0.21 10-Q · filed 2023-08-04 | -$0.44 10-Q · filed 2023-08-04 | -$0.80 derived: net income ÷ weighted average shares · filed 2023-08-04 | -$0.97 derived: net income ÷ weighted average shares · filed 2023-08-04 |
| 2022-03-31 | -$0.23 10-Q · filed 2023-05-05 | -$0.60 derived: net income ÷ weighted average shares · filed 2023-05-05 | -$0.77 derived: net income ÷ weighted average shares · filed 2023-05-05 | -$1.00 derived: net income ÷ weighted average shares · filed 2023-05-05 |
| 2021-12-31 | -$0.37 derived: net income ÷ weighted average shares · filed 2023-03-13 | -$0.54 derived: net income ÷ weighted average shares · filed 2023-03-13 | -$0.77 derived: net income ÷ weighted average shares · filed 2023-03-13 | $1.78 10-K · filed 2023-03-13 |
| 2021-09-30 | -$0.17 10-Q · filed 2022-11-08 | -$0.40 derived: net income ÷ weighted average shares · filed 2022-11-08 | $2.15 10-Q · filed 2022-11-08 | $1.80 derived: net income ÷ weighted average shares · filed 2022-11-08 |
| 2021-06-30 | -$0.23 10-Q · filed 2022-08-09 | $2.32 10-Q · filed 2022-08-09 | $1.98 derived: net income ÷ weighted average shares · filed 2022-08-09 | $1.78 derived: net income ÷ weighted average shares · filed 2022-08-09 |
| 2021-03-31 | $2.55 10-Q · filed 2022-05-10 | $2.25 derived: net income ÷ weighted average shares · filed 2022-05-10 | $2.06 derived: net income ÷ weighted average shares · filed 2022-05-10 | $1.76 derived: net income ÷ weighted average shares · filed 2022-05-10 |
| 2020-12-31 | -$0.34 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$0.62 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$1.02 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$1.39 10-K · filed 2022-03-15 |
| 2020-09-30 | -$0.28 10-Q · filed 2021-11-10 | -$0.68 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$1.04 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$0.41 10-Q · filed 2021-08-16 | -$0.77 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$0.37 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |